Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
Authors:
- 14 December 2016
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 33 (3) , 519-527
Abstract
Objective: The objective of this study was to estimate resource utilization and expenditures for patients with acute myeloid leukemia (AML) in a real-world claims database. Research design and methods: AML patients were identified in MarketScan claims databases between 1 January 2009 and 31 January 2015. Patients had a minimum of two AML diagnosis codes, hospitalization within 14 days after initial diagnosis, and ≥6 months of enrollment before initial diagnosis. Patients were monitored from first-line induction to a record of remission. A subset had a record of a second treatment period, defined as time from relapse to remission. Patient demographics, AML risk factors, and comorbidities were recorded. Descriptive analysis of utilization and expenditures (in 2014 $US) were reported for each cohort. Results: The inclusion criteria were met in 1597 patients (mean age, 58.4 years; 51.0% male). Ninety percent of patients had ≥1 risk factor for AML. Mean (SD) healthcare expenditures for patients from first-line induction to remission (n = 681) were $208,857 ($152,090). Of the 157 who had a record of relapse, 70 had a record of a second remission. Expenditures for these patients (n = 70) from relapse to remission were $142,569 ($208,307); 60% were admitted to a hospital for a mean of 18.5 hospital days, and 20% had ≥1 emergency room visit. Conclusions: Although this claims-based analysis is limited by a lack of generalizability to noninsured populations and potential underreporting of certain events and diagnoses, we found that treating AML patients poses a significant healthcare burden, during both first-line induction and relapse. With people living longer, the number of cases of AML is expected to increase in the future.Keywords
Funding Information
- Pfizer Inc.
This publication has 20 references indexed in Scilit:
- Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysisExperimental Hematology & Oncology, 2014
- Long-Term Medical Costs and Life Expectancy of Acute Myeloid Leukemia: A Probabilistic Decision ModelValue in Health, 2014
- Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and CostsApplied Health Economics and Health Policy, 2013
- Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid LeukemiaStem Cells, 2012
- Induction-related cost of patients with acute myeloid leukaemia in FranceInternational Journal of Clinical Pharmacy, 2011
- PCN47 CHANGE OF ANTIFUNGAL TREATMENT PATTERNS AND ASSOCIATED COSTS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER CHEMOTHERAPY IN A GERMAN HOSPITAL FROM 2004 TO 2006Value in Health, 2010
- Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapseHaematologica, 2010
- Treatment of Acute Myeloid Leukemia with Hematopoietic Stem Cell TransplantationFuture Oncology, 2009
- Outcomes and charges of elderly patients with acute myeloid leukemiaAmerican Journal of Hematology, 2006
- Reducing mortality associated with immediate treatment complications of adult leukemiasSeminars in Hematology, 2001